Business Information
The company's principal activity is to develop and commercialize therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company's programs are directed towards symptom management and supportive care for HIV infection and cancer. The products developed by the company include methylnaltrexone (mntx), pro 542, pro 140, provax, gmk vaccine and psma.
|
|
Name |
Title
|
Email
|
| Alan Houghton | Chmn. - Scientific Advisory Board | N/A | | Kurt Briner | Co - Chmn. | N/A | | Paul Jacobson | Co - Chmn. | N/A | | Paul Maddon | Founder, CEO, Chief Science Officer | N/A | | Robert McKinney | CFO, Sr. VP - Finance, Operations, Treasurer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 69,906 | (21,618) | | 2005 | 9,486 | (69,429) | | 2004 | 9,576 | (42,018)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
